CABA
Cabaletta Bio, Inc.Company Information
- Company Name
- Cabaletta Bio, Inc.
- CIK
- CIK0001759138
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CABA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CABA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-21
- Last sale
- 2024-01-19
- Shares purchased (TTM)
- 132,073
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 72,525,170
- Shares outstanding
- 112,025,474
- Ownership
- 64.74%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 28.04%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 225 | 117 | 83 | 60 | 146 | 132 | 164 | 171 | 179 | 175 | 193 | 116 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 231 | 122 | 139 | 165 | 198 | 135 | 167 | 186 | 206 | 227 | 244 | 166 | ||||||
| Short Term Investments | 0 | 0 | 51 | 100 | 49 | - | 0 | 12 | 25 | 49 | 48 | 49 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 6 | 5 | 5 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 2 | ||||||
| Property Plant And Equipment Net | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Finance Lease Right Of Use Asset | 12 | 17 | 16 | 16 | 17 | 20 | 7 | - | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 6 | 2 | 3 | 4 | 5 | 5 | 6 | 14 | 6 | 8 | 5 | 4 | ||||||
| Other Assets Noncurrent | 6 | 5 | 5 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Assets | 257 | 148 | 165 | 190 | 225 | 165 | 185 | 204 | 217 | 240 | 254 | 173 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 6 | 6 | 7 | 8 | 7 | 6 | 5 | 2 | 4 | 6 | 5 | 4 | ||||||
Liabilities Current | ||||||||||||||||||
| Finance Lease Liability Current | 15 | 21 | 21 | 18 | 16 | 15 | 6 | - | - | - | 0 | - | ||||||
| Liabilities Current | 40 | 42 | 50 | 46 | 42 | 34 | 27 | 23 | 18 | 18 | 16 | 11 | ||||||
| Operating Lease Liability Current | 4 | 2 | 3 | 4 | 4 | 4 | 4 | 8 | 7 | 7 | 4 | 3 | ||||||
| Finance Lease Liability Noncurrent | 5 | 3 | 3 | 5 | 4 | 8 | 3 | - | - | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 1 | - | 0 | 0 | 1 | 1 | 2 | 7 | 0 | 1 | 1 | 2 | ||||||
| Liabilities | 46 | 45 | 53 | 50 | 46 | 44 | 33 | 30 | 18 | 19 | 17 | 12 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 822 | 664 | 629 | 614 | 609 | 507 | 501 | 491 | 485 | 480 | 469 | 373 | ||||||
| Stockholders Equity | 211 | 103 | 112 | 139 | 178 | 122 | 152 | 174 | 200 | 222 | 236 | 161 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -611 | -560 | -517 | -475 | -430 | -385 | -349 | -317 | -286 | -258 | -233 | -212 | ||||||
| Liabilities And Stockholders Equity | 257 | 148 | 165 | 190 | 225 | 165 | 185 | 204 | 217 | 240 | 254 | 173 | ||||||
| Voting Common Stock | 0 | 0 | - | 0 | -6 | 6 | - | -1 | 1 | 0 | - | -3 | ||||||
| Nonvoting Common Stock | 0 | 0 | - | 0 | -6 | 6 | - | -1 | 1 | 0 | - | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | - | - | 100 | 96 | 91 | - | 51 | 49 | 48 | 48 | 48 | 42 | ||||||
| Shares Outstanding | - | - | 100 | 96 | 91 | - | 51 | 49 | 48 | 48 | 48 | 42 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCabaletta Bio, Inc. (CABA) — SEC Financial Statements & Analysis
Cabaletta Bio, Inc. (CABA) is a biological products, (no diagnostic substances) company, incorporated in DE. Cabaletta Bio, Inc. trades on Nasdaq as: CABA. Cabaletta Bio, Inc. (CABA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Cabaletta Bio, Inc. carries a market cap of $470.11M, a P/E ratio of -2.59x, a P/B ratio of 2.23x, an enterprise value of $264.98M, and an EV/EBITDA multiple of -1.44x. On profitability, it posts a Return on Equity (ROE) of -93.20%, a Return on Assets (ROA) of -75.36%, and a Return on Invested Capital (ROIC) of -632.47%. Per share, it reports EPS of $-1.20, diluted EPS of $-1.20, free cash flow per share of $-1.02, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 25.67% year-over-year and EPS growth of -48.56% year-over-year. On the balance sheet, it maintains a current ratio of 5.79x, a quick ratio of 5.64x, working capital of $191.12M, a debt-to-equity ratio of 0.22x, a debt ratio of 0.18, an interest coverage ratio of -80.94x, free cash flow of $-154.21M (TTM), and net debt of $-205.13M. Figures sourced from SEC EDGAR.
- Market Cap
- $470.11M
- P/E TTM
- -2.59x
- EPS TTM
- $-1.20
- P/B TTM
- 2.23x
- ROE TTM
- -93.20%
- ROA TTM
- -75.36%
- Debt To Equity
- 0.22x
- Free Cash Flow TTM
- $-154.21M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cabaletta Bio, Inc. in?
Cabaletta Bio, Inc. (CABA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CABA trade on?
Cabaletta Bio, Inc. (CABA) trades on the Nasdaq.
Where is Cabaletta Bio, Inc. incorporated?
Cabaletta Bio, Inc. is incorporated in DE.
When was Cabaletta Bio, Inc. (CABA)'s most recent SEC filing?
Cabaletta Bio, Inc. (CABA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CABA's market cap?
Cabaletta Bio, Inc. (CABA) has a market capitalization of $470.11M as of 2026-06-30.
What is CABA's EPS (earnings per share)?
Cabaletta Bio, Inc. (CABA)'s trailing twelve month EPS is $-1.20 as of 2026-06-30.
What is CABA's ROE (return on equity)?
Cabaletta Bio, Inc. (CABA)'s trailing twelve month Return on Equity (ROE) is -93.20% as of 2026-06-30.
What is CABA's ROA (return on assets)?
Cabaletta Bio, Inc. (CABA)'s trailing twelve month Return on Assets (ROA) is -75.36% as of 2026-06-30.
What is CABA's ROIC (return on invested capital)?
Cabaletta Bio, Inc. (CABA)'s trailing twelve month Return on Invested Capital (ROIC) is -632.47% as of 2026-06-30.
What is CABA's EV/EBITDA?
Cabaletta Bio, Inc. (CABA)'s trailing twelve month EV/EBITDA is -1.44x as of 2026-06-30.